Literature DB >> 16571967

Reversal of profound rocuronium neuromuscular blockade by sugammadex in anesthetized rhesus monkeys.

Hans D de Boer1, Jan van Egmond, Francien van de Pol, Anton Bom, Leo H D J Booij.   

Abstract

BACKGROUND: Reversal of neuromuscular blockade can be accomplished by chemical encapsulation of rocuronium by sugammadex, a synthetic gamma-cyclodextrin derivative. The current study determined the feasibility of reversal of rocuronium-induced profound neuromuscular blockade with sugammadex in the anesthetized rhesus monkey using train-of-four stimulation.
METHODS: Four female rhesus monkeys each underwent three experiments. In each experiment, first, a 100-microg/kg dose of rocuronium was injected and spontaneous recovery was monitored. After full recovery, a 500-microg/kg dose of rocuronium was injected. Up to this point, all three experiments in a single monkey were identical. One minute after this rocuronium injection, either one of the two tested dosages of sugammadex (1.0 or 2.5 mg/kg) was injected or saline was injected.
RESULTS: Injection of 100 microg/kg rocuronium resulted in a mean neuromuscular blockade of 93.0% (SD = 4%), and profound blockade was achieved by injection of 500 microg/kg. In all experiments, a 100% neuromuscular blockade was achieved at this dose. After injection of the high rocuronium dose, the 90% recovery of the train-of-four ratio took 28 min (SD = 7 min) after saline, 26 min (SD = 9.5 min) after 1 mg/kg sugammadex, and 8 min (SD = 3.6 min) after 2.5 mg/kg sugammadex. Signs of residual blockade or recurarization were not observed. Injection of sugammadex had no significant effects on blood pressure or heart rate.
CONCLUSIONS: Chemical encapsulation of rocuronium by sugammadex is a new therapeutic mechanism allowing effective and rapid reversal of profound neuromuscular blockade induced by rocuronium in anesthetized rhesus monkeys.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16571967     DOI: 10.1097/00000542-200604000-00016

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  13 in total

Review 1.  [Sugammadex. New pharmacological concept for antagonizing rocuronium and vecuronium].

Authors:  H J Sparr; L H Booij; T Fuchs-Buder
Journal:  Anaesthesist       Date:  2009-01       Impact factor: 1.041

2.  Reversal of rocuronium-induced neuromuscular block by sugammadex is independent of renal perfusion in anesthetized cats.

Authors:  Lonneke M Staals; Hans D de Boer; Jan van Egmond; Frank Hope; Francien van de Pol; Anton H Bom; Jacques J Driessen; Leo H D J Booij
Journal:  J Anesth       Date:  2011-01-12       Impact factor: 2.078

3.  Safety, tolerability and pharmacokinetics of sugammadex using single high doses (up to 96 mg/kg) in healthy adult subjects: a randomized, double-blind, crossover, placebo-controlled, single-centre study.

Authors:  Pierre A M Peeters; Michiel W van den Heuvel; Emiel van Heumen; Paul C C M Passier; Jean M W Smeets; Thijs van Iersel; Alex Zwiers
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

4.  Cyclodextrins sequester neuroactive steroids and differentiate mechanisms that rate limit steroid actions.

Authors:  H-J Shu; C-M Zeng; C Wang; D F Covey; C F Zorumski; S Mennerick
Journal:  Br J Pharmacol       Date:  2006-12-11       Impact factor: 8.739

5.  The influence of neuroactive steroid lipophilicity on GABAA receptor modulation: evidence for a low-affinity interaction.

Authors:  Mariangela Chisari; Lawrence N Eisenman; Kathiresan Krishnan; Achintya K Bandyopadhyaya; Cunde Wang; Amanda Taylor; Ann Benz; Douglas F Covey; Charles F Zorumski; Steven Mennerick
Journal:  J Neurophysiol       Date:  2009-06-24       Impact factor: 2.714

6.  Simulation of the reversal of neuromuscular block by sequestration of the free molecules of the muscle relaxant.

Authors:  Vladimir Nigrovic; Shashi B Bhatt; Anton Amann
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-09-21       Impact factor: 2.410

Review 7.  Optimization of Intraoperative Neural Monitoring of the Recurrent Laryngeal Nerve in Thyroid Surgery.

Authors:  Chia-Yuan Hsieh; Hao Tan; Hui-Fang Huang; Tzu-Yen Huang; Che-Wei Wu; Pi-Ying Chang; David-Vi Lu; I-Cheng Lu
Journal:  Medicina (Kaunas)       Date:  2022-03-30       Impact factor: 2.948

8.  Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent.

Authors:  Mark Welliver; John McDonough; Nicholas Kalynych; Robert Redfern
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

9.  Update on the management of neuromuscular block: focus on sugammadex.

Authors:  Hans D de Boer; Jan van Egmond; Jacques J Driessen; Leo H D Booij
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

10.  Selective reversal of muscle relaxation in general anesthesia: focus on sugammadex.

Authors:  Sorin J Brull; Mohamed Naguib
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.